Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Biogen paid Ionis a US $ 60 million one-time upfront payment
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Partnering to build biosynthesis processes and a pharmaceutical production platform
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Subscribe To Our Newsletter & Stay Updated